sq-11725 has been researched along with Ascites in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Advani, S; Cao, Y; El-Serag, HB; Kanwal, F; Kramer, J; Shukla, R; Tansel, A; Walder, A; Ying, J | 1 |
| Bissoli, F; Borroni, G; Cazzaniga, M; de Franchis, R; Lorenzano, E; Maggi, A; Panzeri, A; Salerno, F; Visentin, S | 1 |
| Aracil, C; Balanzó, J; González, B; Guarner, C; Kolle, L; López-Balaguer, JM; Miñana, J; Soriano, G; Villanueva, C | 1 |
| Amodio, P; Angeli, P; Cavallarin, G; Donada, C; Enzo, E; Gatta, A; Marin, R; Merkel, C; Sebastianelli, G; Torboli, P | 1 |
| Amodio, P; Bolognesi, M; Cavallarin, G; Donada, C; Felder, M; Gatta, A; Marin, R; Mazzaro, C; Merkel, C; Sacerdoti, D; Sebastianelli, G; Torboli, P | 1 |
| Calès, P; Ideo, G; Lebrec, D; Pagliaro, L; Pascal, JP; Pasta, L; Poynard, T | 1 |
1 review(s) available for sq-11725 and Ascites
| Article | Year |
|---|---|
Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter
Topics: Adrenergic beta-Antagonists; Ascites; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Male; Meta-Analysis as Topic; Middle Aged; Nadolol; Prognosis; Propranolol | 1991 |
5 trial(s) available for sq-11725 and Ascites
| Article | Year |
|---|---|
Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Blood Pressure; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Heart Rate; Humans; Isosorbide Dinitrate; Kidney; Liver Cirrhosis; Male; Middle Aged; Nadolol; Survival Rate; Treatment Outcome; Vasodilator Agents | 2002 |
Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.
Topics: Adrenergic beta-Antagonists; Aged; Ascites; Esophageal and Gastric Varices; Female; Hemodynamics; Hepatic Encephalopathy; Humans; Hypertension, Portal; Isosorbide Dinitrate; Liver Circulation; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nadolol; Prognosis | 2004 |
Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale.
Topics: Adolescent; Adult; Aged; Ascites; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Humans; Isosorbide Dinitrate; Kidney; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Nadolol; Venous Pressure | 1995 |
Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Isosorbide Dinitrate; Liver Cirrhosis; Male; Middle Aged; Nadolol; Randomized Controlled Trials as Topic | 2000 |
Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter
Topics: Adrenergic beta-Antagonists; Ascites; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Male; Meta-Analysis as Topic; Middle Aged; Nadolol; Prognosis; Propranolol | 1991 |
1 other study(ies) available for sq-11725 and Ascites
| Article | Year |
|---|---|
Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Ascites; Cohort Studies; Comorbidity; Dose-Response Relationship, Drug; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Heart Rate; Humans; Liver Cirrhosis; Male; Middle Aged; Nadolol; Primary Prevention; Proportional Hazards Models; Propranolol; Retrospective Studies; Risk Assessment; Risk Factors; United States; United States Department of Veterans Affairs | 2016 |